

# Protective Effects of Adenosine Receptor Agonist in a Cirrhotic Liver Resection Model

Emil Iskandarov,<sup>1</sup> Pramod Kadaba Srinivasan,<sup>2,\*</sup> Wang Xin,<sup>3</sup> Christian Bleilevens,<sup>4</sup> Mamdouh Afffy,<sup>2</sup> Astrit Hamza,<sup>5</sup> Lai Wei,<sup>3</sup> Koichiro Hata,<sup>6</sup> Boyukkishi Agayev,<sup>1</sup> and Rene Tolba<sup>2</sup>

<sup>1</sup>Department of Hepato-biliary and Pancreas Surgery, Scientific Center of Surgery named after academician M.A.Topchubashov, Baku, Azerbaijan

<sup>2</sup>Institute for Laboratory Animal Science and Experimental Surgery, University Hospital, RWTH Aachen University, Aachen, Germany

<sup>3</sup>Tongji Hospital, Tongji Medical College, Department of Surgery, Division of Transplantation, Wuhan, China

<sup>4</sup>Department of Anaesthesiology, University Hospital, RWTH Aachen University, Aachen, Germany

<sup>5</sup>Department of Abdominal Surgery, University Clinical Center of Kosovo, Prishtina, Kosovo

<sup>6</sup>Department of Hepatobiliary, Pancreas and Transplant Surgery, Kyoto University, Yoshidahonmachi, Sakyo Ward, Kyoto, Japan

\* Corresponding author: Pramod Kadaba Srinivasan, Institute for Laboratory Animal Science and Experimental Surgery, University Hospital RWTH Aachen, Aachen, Germany. Tel: +49-2418089855, Fax: +49-2418082462, E-mail: pramod.kadaba@gmail.com

Received 2016 February 02; Revised 2016 March 07; Accepted 2016 June 22.

## Abstract

**Objectives:** To investigate the role of CGS21680, a selective adenosine A2A receptor agonist, on a bile-duct-ligated cirrhotic liver resection model in rats.

**Methods:** Male Wistar rats were allotted into 3 groups (n = 7 per time-point): the control group, the bile duct ligation + CGS21680 group (BDL + CGS), and the bile duct ligation group (BDL). Biliary cirrhosis had been previously induced by ligation of the common bile duct in the BDL + CGS and BDL groups. After 2 weeks, the animals underwent partial hepatectomy (50%). The BDL + CGS group received a single dose of CGS21680 15 minutes prior to hepatectomy. Blood samples were collected and analyzed.

**Results:** Aspartate transaminase levels were found to be lower in the control vs BDL groups (1, 3, and 24 h) (P < 0.01) and the BDL + CGS (1 and 3 hours) (P < 0.01) and BDL + CGS vs BDL (24 hours) (P < 0.05) groups. Hepatic flow was measured and BDL showed significantly lower values at the 3, 24, and 168 h time-points compared to the control (P < 0.01) and BDL + CGS groups (P < 0.05 at 3 and 168 hours; P < 0.01 at 24 h). O2C velocity was reduced in the BDL compared to the control group (P < 0.001 at 3 hours; P < 0.01 at 24 and 168 hours) and the BDL + CGS group (P < 0.01 at 24 hours). Interleukin-6 levels were abrogated in the BDL + CGS (P < 0.05) and control (P < 0.01) groups versus BDL. Histone-bound low-molecular-weight DNA fragments in the BDL + CGS (P < 0.01) and control (P < 0.05) groups were low compared to the BDL group.

**Conclusions:** Administration of CGS21680, an adenosine receptor agonist, after the resection of bile-duct-ligated cirrhotic livers led to improved liver function, regeneration, and microcirculation.

**Keywords:** CGS21680, A2A Adenosine Receptors, liver Cirrhosis, liver Resection, Interleukin-6

## 1. Background

Liver cirrhosis (LC) is a deleterious clinical condition that leads to irreversible damage to the organ. LC distorts the normal architecture of the liver and is characterized by fibrosis, hepatic injury, and nodular regeneration. These changes lead to impaired function and ultimately to organ failure or liver cancer. The causes of LC can be infectious (e.g. viral hepatitis B, C, and D), genetic disease (e.g. Wilson's disease, cystic fibrosis, hemochromatosis), drugs and poisons (e.g. alcohol, methotrexate), or other conditions such as chronic biliary obstruction.

According to the world health organization and the European association for the study of the liver, 1.8% of all deaths in Europe are due to LC, at a rate of 170,000 deaths annually (1). Hepatocellular carcinoma (HCC) is one of the leading causes of death worldwide, and LC is one of

the major risk factors for its development (2). Approximately 85% - 95% of HCCs occur in patients with LC (3, 4). HCC is associated with intrahepatic inflammation, oxidative DNA damage, and oxidative stress (5). Chronic inflammation is known to be the root cause for many diseases due to increased proinflammatory cytokines (6). Studies have shown that agonists for G-protein coupled receptors, such as cell-surface adenosine purinergic receptors, upregulate the immunosuppressive cyclic AMP in immune cells. Ohta and Sitkovsky showed that attenuation of inflammation and tissue damage in vivo was due to the non-redundant role of A2A adenosine receptors (A2ARs) (6).

A2ARs are ubiquitously present in almost all organs; however, they are highly expressed in the brain and play an important role in the regulation of glutamic acid and the release of dopamine. These features make it an ideal therapeutic target for treating certain conditions, includ-

ing Parkinson's disease, depression, and pain (7-9). Evidence suggests that they are also expressed in the liver, especially in Kupffer cells, hepatocytes, and stellate cells (10-12). Mice devoid of A2AR have shown elevated levels of proinflammatory cytokines, in line with elevated biochemical parameters and the histological data.

Surgical interventions, such as liver transplantation, partial hepatectomy, and tumor resection, can lead to blood loss and ischemia-reperfusion injury (IRI) of the liver. Portal triad clamping, also called Pringle's maneuver, is an effective technique to control blood loss during liver resection (13). However, IRI following Pringle's maneuver may lead to hepatic dysfunction and liver insufficiency (14). IRI triggers a cascade of inflammatory responses in damaged tissues. Extensive research has shown that A2AR activation promotes hepatic ischemic preconditioning both in vivo and in vitro (15-18). A recent study by Dal Ponte et al. showed that ischemic postconditioning using CGS21680, an A2AR agonist, has protective effects on hepatocytes (17).

## 2. Objectives

Considering all of the beneficial effects of A2ARs in previous studies, we used CGS21680, a selective A2AR agonist, in the present study. We hypothesized that the administration of CGS21680 in cirrhotic livers induced by bile duct ligation would ameliorate reperfusion-associated injury in an experimental rat model and may improve regeneration.

## 3. Methods

All experiments were conducted in accordance with German federal law and European directive 2010/63/EU on the protection of animals used for scientific procedures. Our experiments were also in compliance with the guide for the care and use of laboratory animals (8th edition, NIH publication, 2011, USA). The governmental care and use committee (LANUV), Recklinghausen, NRW, Germany, granted official permission. Male Wistar rats (Charles River GmbH, Sulzfeld, Germany) weighing 250 - 350 g were used in this study. The animals were housed under SPF-conditions according to FELASA guidelines ([www.felasa.org](http://www.felasa.org)) in a temperature- and humidity-controlled environment (certified according to DIN-ISO 9001/2008) with a 12 hour light/dark cycle. They were allowed food (standard rat diet, Sniff-Spezialdiäten GmbH, Soest, Germany) and water ad libitum.

### 3.1. Experimental Groups and Operative Procedures

The animals were randomly assigned to the following 3 groups: the control group, with no bile duct ligation (n=7);

the bile duct ligation group that received CGS21680 treatment (BDL + CGS group) (n = 7); and the bile duct ligation group that did not receive CGS treatment (BDL group) (n = 7). These groups were further divided into 4 subgroups according to varying time-points of observation time (OT): 1, 3, 24, and 168 h OT after liver resection (n = 7 at each time-point in each group). General anesthesia was induced by inhalation of 5 vol% of isoflurane (Abbot GmbH and Co. KG, Wiesbaden, Germany) and 5 L/min of oxygen. Thereafter, the anesthesia concentration was reduced and maintained at 2 vol% with 2 L/min of oxygen. Cefuroxime sodium (16 mg/kg per 24 hours) (Cefuroxim Fresenius; Fresenius Kabi Deutschland GmbH, Bad Hamburg, Germany), a preoperative prophylactic antibiotic, was injected subcutaneously. As perioperative analgesia, buprenorphine (0.1 mg/kg per 24 hours) (Temgesic; Essex Pharma, München, Germany) was injected for 24 hours or up to 3 days after surgery.

Hamza et al. previously described the following surgical procedure (3). A midline laparotomy was performed to expose the abdomen. In the BDL + CGS and BDL groups, we induced secondary biliary liver cirrhosis by ligating the bile duct. Next, through a small incision, the duodenum was reached in order to place the common bile duct under tension. After isolating the common bile duct, the duct was ligated twice using PDS-6.0 (Ethicon, Johnson and Johnson, Lenneke Marelaan, Belgium) and then dissected. The abdominal wall was closed in 2 layers, the first with continuous sutures, then the skin with interrupted sutures. The animals were then placed in a special intensive care unit (Vetario; Brinsea products Ltd., North Somerset, United Kingdom) for recovery, with warmed air (30 - 35°C) for at least 15 min. After 2 weeks, the animals underwent partial liver resection of 50% of the liver mass (left liver lobe [LLL], anterior caudate [AC] lobe, and posterior caudate [PC] lobe). In the BDL + CGS group, the animals were treated 15 minutes before the resection with a single dose of a selective A2AR agonist, CGS21680 (Sigma Chemicals, Deisenhofen, Germany), at a dose of 10 µg/kg body weight intravenously via the penile vein. All surgical procedures were performed under aseptic conditions. In the control group, the same surgical procedure was performed without prior BDL and CGS administration.

### 3.2. Enzyme Release/Hepatocellular Damage

As a general parameter of hepatocellular damage, aspartate transaminase (AST) release was measured at 1, 3, 24, and 168 hours. Serum samples were collected after liver resection and assessed by a standard enzymatic method using a Vitros 250 analyzer (Ortho Clinical Diagnostics, NJ, USA).

### 3.3. Microcirculation of the Liver

We used a laser Doppler flowmeter combined with a near-infrared spectrophotometry device (O2C: Oxygen to See; LEA Medizintechnik GmbH, Giessen, Germany) to measure the microcirculation of the liver. Portal venous flow (PVF) was measured with a transit-time perivascular flowmeter (T403; Transonic Systems, Inc., Ithaca, NY, USA) using a Transonic flow probe (MA2PSB; Transonic Systems, Inc.).

### 3.4. In situ Cell Death Detection

Apoptosis was quantified at 24 hours using an enzyme-linked immunosorbent assay (ELISA) kit (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's instructions. The assay detected low-molecular-weight histone-bound DNA fragments in the tissue lysate. Results were expressed as arbitrary units (AU).

### 3.5. Proinflammatory Cytokines

Serum levels of interleukin-6 (IL-6) 3 hours after reperfusion were measured with rat ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.

### 3.6. Histopathology

Liver tissue sections were collected after resection and the samples were stored in 100 g/L of paraformaldehyde for 24 hours (fixation). Later, the samples were transferred to 40 g/L of paraformaldehyde for storage. The tissue samples were then embedded, sectioned, and stained using hematoxylin and eosin (H&E). Examinations of all slides were performed using a Leica DM 2500 optic microscope (Wetzlar, Germany) under  $\times 400$  magnification. An in-house pathologist who was blinded to the experimental conditions scored the lesions on a scale of 1-5 (1 = no or negligible changes, lesions affecting 0% - 10% of the field; 2 = mild, lesions affecting 10% - 30% of the field; 3 = mild to moderate, lesions affecting 30% - 60% of the field; 4 = moderate to severe, lesions affecting 60% - 80% of the field; and 5 = severe; lesions affecting > 80% of the field).

### 3.7. TUNEL Staining

Histological evaluation for apoptosis was done by in situ labeling for DNA fragmentation using terminal deoxynucleotidyl transferase-mediated deoxy-UTP nick-end labeling (TUNEL). The TUNEL test was performed using the standard protocol and a commercial kit (Boehringer Mannheim, Mannheim, Germany) provided by the manufacturer. The counting of TUNEL-positive cells was performed with ImageJ software (version 1.48a for Mac OSX, National Institutes of Health, MD, USA), in 5 random fields. The results are expressed as percentage of positive cells.

### 3.8. Ki-67 Staining

As described previously by Hamza et al. (3), tissue sections were subjected to immunohistochemical staining using the avidin-biotin complex method and diaminobenzidine. The antibodies used in this study were monoclonal mouse Ki-67 (MIB5, 1:10; DACO, Glostrup, Denmark) for assessing the cell proliferation rate.


### 3.9. Statistical Analysis

The results are expressed as mean  $\pm$  standard error of mean (mean  $\pm$  SEM) for each group. The statistical analyses between the groups were performed using either one-way or two-way analysis of variance (ANOVA) and Tukey's multiple comparison test. Values of  $< 0.05$  were considered to be statistically significant. All statistical calculations were made using Prism 6.0f for Mac OS X (GraphPad Software Inc., San Diego, CA, USA).

## 4. Results

AST release was measured as a general parameter of hepatocellular damage. The 24 hours post-resection time-point showed significantly higher levels of AST in the BDL group ( $281 \pm 43$  IU/L) compared to the BDL + CGS group ( $193 \pm 25$  IU/L). The control group showed significantly lower AST ( $126 \pm 18$  IU/L) compared to the BDL group; however, there was no significant difference recorded between the control and BDL + CGS groups. At the end of 168 hours, there were no significant differences recorded between the three groups: control ( $40 \pm 11$  IU/L), BDL ( $70 \pm 15$  IU/L), and BDL + CGS ( $72 \pm 13$  IU/L) (Figure 1).


**Figure 1.** Release of AST in the Serum at 1, 3, 24, and 168 hours After Liver Resection



Results are expressed as mean  $\pm$  SEM; two-way ANOVA, Tukey's multiple comparison test. a,  $P < 0.01$  vs. BDL and BDL + CGS (1 hour, 3 hours); b,  $P < 0.0001$  vs. BDL; c,  $P < 0.05$  vs. BDL + CGS ( $n = 7$ ).

O2C flow was measured to evaluate microcirculation in the liver. O2C flow values were significantly lower at 3 h in the BDL group ( $122 \pm 7$  AU) compared to the control

(175 ± 9 AU) and BDL + CGS (167 ± 8 AU) groups. Similarly, the BDL group showed significantly lower values at the 24 hours and 168 hours time-points (137 ± 13 AU and 123 ± 8 AU, respectively) compared to the control group (182 ± 6 AU and 175 ± 8 AU, respectively) and the BDL + CGS group (183 ± 18 AU and 172 ± 17 AU, respectively) (Figure 2A).




**Figure 2.** A, O2C flow measurement in the liver at 1, 3, 24, and 168 hours. Results are expressed as mean ± SEM; two-way ANOVA, Tukey's multiple comparison test. a, P < 0.01 vs. control (3 hours, 24 hours, 168 hours); b, P < 0.05 vs. BDL; c, P < 0.01 vs. BDL (n = 7). B, O2C velocity measurement in the liver at the four time-points. Results are expressed as mean ± SEM; two-way ANOVA, Tukey's multiple comparison test. a, P < 0.001 vs. control; b, P < 0.01 vs. control; c, P < 0.01 vs. BDL (n = 7).

Similar to O2C flow, O2C velocity was recorded at all time-points to assess the volume of blood flow in the organ. The BDL group (18 ± 0 AU) showed significantly lower values at 24 hours compared to the control group (22 ± 0 AU) and the BDL + CGS group (22 ± 1 AU). Interestingly, the BDL + CGS group showed values similar to those of the control group (Figure 2B).


PVF was measured at all time-points, and levels were significantly different at the 24 hours time-point between the control group (24 ± 2 mL/min) and the BDL group (13 ± 2 mL/min). However, there were no significant differences between the BDL + CGS group (20 ± 3 mL/min) and the other two (Figure 3).

IL-6 levels are known to be upregulated in tissue damage, leading to inflammation; hence, we measured IL-6 to



**Figure 3.** PVF after liver resection at the four time-points. Results are expressed as mean ± SEM; two-way ANOVA, Tukey's multiple comparison test. a, P < 0.01 vs. control (n = 7).


assess the extent of this damage. The BDL group showed significantly higher levels of IL-6 (512.6 ± 83.99 pg/mL) compared to the control (197.4 ± 8.80 pg/mL) and BDL + CGS (307.8 ± 31.11 pg/mL) groups (Figure 4).



**Figure 4.** Release of IL-6 in the serum at the 3 hours time-point. Results are expressed as mean ± SEM; one-way ANOVA, Tukey's multiple comparison test. a, P < 0.01 vs. BDL; b, P < 0.05 vs. BDL (n = 7).

To assess the extent of apoptosis, we measured histone-bound DNA fragments in the tissue lysate at the 24 hours time-point. The BDL group showed significantly higher levels of these fragments (0.081 ± 0.011 AU) in comparison to the control (0.045 ± 0.006 AU) and BDL + CGS (0.027 ± 0.005 AU) groups (Figure 5).

Histological analysis and scoring revealed that the control group was the least affected, with a mean score of 1 (negligible damage), while the BDL + CGS group showed a mean score of 2.2 (mild damage) and the BDL group showed a mean score of 4.1 (moderate to severe damage) (Figure 6). Quantification of TUNEL-positive cells showed



**Figure 5.** Measurement of low-molecular-weight histone-bound DNA fragments at the 24-hours time-point to assess the extent of apoptosis. Results are expressed as mean  $\pm$  SEM; one-way ANOVA, Tukey's multiple comparison test. a,  $P < 0.05$  vs. BDL; b,  $P < 0.01$  vs. BDL ( $n = 7$ ).

significantly higher numbers in the BDL group ( $2.9 \pm 0.82$  AU) compared to the control ( $0.04 \pm 0.04$  AU) and BDL+CGS ( $0.4 \pm 0.24$  AU) groups (Table 1). Hepatocyte proliferation was evaluated with immunohistochemistry showing Ki-67-positive nuclei. The BDL + CGS group ( $9.3 \pm 3.2$  AU) showed significantly higher positively-stained nuclei compared to the BDL group ( $1.0 \pm 0.5$  AU) (Table 1).

Values are expressed as mean  $\pm$  SEM; one-way ANOVA. Tukey's multiple comparison test:  $n = 5$ ; a, b  $P < 0.01$  vs BDL; c  $P < 0.05$  vs BDL. BDL: bile duct ligation, BDL + CGS: bile duct ligation + CGS21680.

## 5. Discussion

Liver cirrhosis is a major contributing factor in hepatocellular carcinoma. Mokdad et al., in their systematic analysis, showed the extent of mortality due to LC in 187 countries between the years 1980 and 2010. Their astounding results showed that LC caused more than one million deaths worldwide in the year 2010 (19).

Resection or transplant surgery are still the most accepted treatments for LC and HCC. Surgical interventions carry a higher risk of blood loss; hence, surgeons perform Pringle's maneuver for safe resection of the cirrhotic liver (13). However, Pringle's maneuver is associated with IRI, which can cause many complications, including liver failure (20). Research has shown that IRI is one of the major complications of liver surgery, with exponentially increased postoperative morbidity and mortality (14, 21). Apart from the abovementioned complications, IRI is also the most common reason for early graft dysfunction after liver transplantation (22, 23).


A variety of preventive measures have been recommended to minimize IRI; for example, Peralta et al. showed that ischemic preconditioning could be an option (20). Alchera et al. suggested that A2AR agonists minimize IRI in the liver (24). A2ARs are known to play a very important role in hepatic IRI (6). Increased cellular consumption of adenosine triphosphate leads to accumulation of extracellular adenosine, which is believed to exert cytoprotective effects on ischemic tissues (25). Research shows that adenosine may inhibit the synthesis of inflammatory parameters via A2 receptor stimulation, or by averting the downregulation of endothelial nitric oxide synthase during IRI (18, 26) Peralta et al. reported that increased adenosine activates A2ARs, leading to increased nitric oxide concentration and thereby blocking hepatic injury during IRI (18). Many studies have suggested that the use of A2AR agonists, such as CGS21680, minimizes hepatic IRI (17, 25, 27).

In the present study, we wanted to test A2AR stimulation in a more clinically relevant model; therefore, we induced LC by ligating the common bile duct. We then evaluated the effect of CGS21680 after cirrhotic liver resection. The main aim was to elucidate the role of CGS21680 in the amelioration of IRI-related (microcirculatory/microvasculature) damage.

Previous studies have shown that stimulation of A2ARs promotes hepatic preconditioning, first in in vitro and then in in vivo experiments (17, 18, 28). In a small-for-size liver transplantation model, Tang et al. showed that activation of A2ARs by administration of CGS21680 improved liver function, decreased portal hypertension, inhibited apoptosis, and decreased neutrophil infiltration (29). Although A2ARs are distributed ubiquitously, their levels are highest in the spleen, thymus, and leucocytes compared to the liver, where levels are rather low (29, 30). Nevertheless, CGS21680 is known to increase hepatocyte viability under hypoxic conditions (15). Research has shown that CGS21680 has protective effects on hepatocytes, such as vasodilation, decreased inflammation, and suppression of apoptosis (29). In our study, we measured AST levels as a general parameter for hepatic function, and noticed that the enzyme levels were significantly abrogated at the 24 hours time-point in the presence of CGS21680. These findings proved the protective effects exerted by CGS21680, which in turn stimulates the A2ARs. Our results are in line with the results reported by Tang et al. in their study involving CGS21680 in small-for-size liver transplantation (29). Liver grafts are susceptible to IRI damage during surgical procedures, such as liver transplantation or resection. Pretreatment of rats with CGS21680 is also known to increase tolerance against IR-related damage (24, 28).

CGS21680 is a highly selective drug for A2ARs, and various researchers have already established the omnipres-

**Figure 6.** Histopathological Findings



H&E staining of liver tissue 24 hours after resection: control (A), BDL + CGS (B), BDL (C); TUNEL staining for apoptotic/necrotic cells, control (D), BDL + CGS (E), BDL (F); immunohistochemical analysis of hepatocyte proliferation with Ki-67 positive nuclei: control (G), BDL + CGS (H), BDL (I). BDL: bile duct ligation; BDL + CGS: bile duct ligation + CGS21680.  $\times 400$ .

**Table 1.** Quantification of TUNEL- and Ki-67-Positive Cells

	Control	BDL + CGS	BDL	P Value
TUNEL (AU)	0.04 $\pm$ 0.04a	0.4 $\pm$ 0.24b	2.9 $\pm$ 0.82	< 0.01
Ki-67 (AU)	4.4 $\pm$ 1.2	9.3 $\pm$ 3.2c	1.0 $\pm$ 0.5	< 0.05

ence of these receptors (16, 31). However, the most interesting feature of A2ARs are their presence in the vasculature, specifically in the smooth muscle and endothelium. A2ARs are known to mediate adenosine-induced vasodilatation in the hepatic arterial bed (HA) (32). Mathie et al. showed that CGS21680 exhibited 3 times greater potency in inducing HA vasodilatation compared to adenosine (32). The vasodilative properties of A2ARs are well established in the aorta, coronary artery, and mesenteric artery (33). In the

present study, PVF showed no significant differences; however, we could demonstrate significantly higher levels of hepatic flow and velocity in the presence of CGS21680. In this way, we could clearly prove that A2AR stimulation with CGS21680 caused vasodilatation in comparison to the BDL group. Furthermore, significantly higher velocity in the CGS21680-treated group validates the vasodilative properties on A2ARs. Nonetheless, the molecular mechanisms behind these results need further investigation.

Liver sinusoidal endothelial cells are known to produce IL-6, a pro-inflammatory cytokine. IL-6 attenuates apoptosis and helps in the regeneration of hepatocytes (34). Inflammation and tissue damage lead to increased levels of IL-6; concurrently, an increased level of IL-6 induces insulin resistance and liver inflammation, especially in patients with non-alcoholic fatty liver disease (34). In this study, we noticed the attenuation of IL-6 release in the presence of CGS21680, the absence of which was correlated to significantly higher levels of IL-6. These results were in line with results previously published by Tang et al. (29). Interestingly, the decreased levels of IL-6 in the BDL + CGS group also showed significantly lower levels of apoptosis. The favorable results of cell death detection and decreased occurrence of TUNEL-positive cells in the BDL + CGS group contribute to the fact that CGS21680 attenuates apoptosis (29).

Histopathological analyses showed moderate to severe damage of liver tissue in the BDL group, with semi-quantitative scores showing an increased level of biliary proliferation in multiple liver lobules. Further analysis of the slides also revealed infiltration of inflammatory cells in certain areas, along with necrotic/apoptotic cells. Minor et al. showed that stimulation of A2ARs better protected pre-damaged cold-stored liver grafts, and there was much less IRI-related damage (35). In another similar study, Ben-Ari et al. showed that rats treated with CGS21680 showed significantly lower levels of apoptotic cells; they also showed that the histological sections revealed a high level of acidophilic bodies (25). Simultaneously, proliferative activity was assessed by the number of Ki-67-positive nuclei enterocytes. The end result showed a significantly lower level of Ki-67-positive cells in the BDL group. These results were in line with the previously obtained histopathological results.

In summary, after 50% liver resection, cirrhotic livers treated with CGS21680 showed significant improvements in their microvasculature and structure. A2AR stimulation provided robust protection against inflammation and apoptosis. However, further confirmatory studies with larger sample sizes are needed in the future. Our preliminary experimental data clearly showed attenuation of AST levels, improved flow and velocity, better-preserved tissue structure, and improved regeneration upon activation of A2ARs. These promising results could promote CGS21680, an A2AR agonist, as a therapeutic option for liver cirrhosis.

## Acknowledgments

The authors thank Ms. Mary S. Elm for language-editing services.

## Footnotes

**Authors' Contribution:** Study concept and design: Rene Tolba and Pramod Kadaba Srinivasan; acquisition of data: Pramod Kadaba Srinivasan, Wang Xin, and Emil Iskandarov; analysis and interpretation of data: Rene Tolba, Pramod Kadaba Srinivasan, Emil Iskandarov, and Mamdouh Afify; drafting of the Manuscript: Pramod Kadaba Srinivasan and Emil Iskandarov; critical revision of the manuscript for important intellectual content: Rene Tolba, Pramod Kadaba Srinivasan, and Koichiro Hata; statistical analysis: Pramod Kadaba Srinivasan, Christian Bleilevens and Astrit Hamza; administrative, technical, and material support: Lai Wei and Boyukkishi Agayev; Study Supervision: Rene Tolba and Pramod Kadaba Srinivasan. Emil Iskandarov and Pramod Kadaba Srinivasan contributed equally.

**Funding/Support:** Dr. Iskandarov was supported by the German academic exchange service (DAAD), No. A/06/09904.

## References

- Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. *J Hepatol.* 2013;**58**(3):593-608.
- Ruzzenente A, Valdegamberi A, Campagnaro T, Conci S, Pachera S, Iacono C, et al. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated?. *World J Gastroenterol.* 2011;**17**(46):5083-8. doi: [10.3748/wjg.v17.i46.5083](https://doi.org/10.3748/wjg.v17.i46.5083). [PubMed: [22171142](https://pubmed.ncbi.nlm.nih.gov/22171142/)].
- Hamza AR, Krasniqi AS, Srinivasan PK, Afify M, Bleilevens C, Klinge U, et al. Gut-liver axis improves with meloxicam treatment after cirrhotic liver resection. *World J Gastroenterol.* 2014;**20**(40):14841-54. doi: [10.3748/wjg.v20.i40.14841](https://doi.org/10.3748/wjg.v20.i40.14841). [PubMed: [25356044](https://pubmed.ncbi.nlm.nih.gov/25356044/)].
- Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. *J Hepatol.* 2008;**48** Suppl 1:S20-37. doi: [10.1016/j.jhep.2008.01.022](https://doi.org/10.1016/j.jhep.2008.01.022). [PubMed: [18304676](https://pubmed.ncbi.nlm.nih.gov/18304676/)].
- Mastron JK, Siveen KS, Sethi G, Bishayee A. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review. *Anticancer Drugs.* 2015;**26**(5):475-86. doi: [10.1097/CAD.0000000000000211](https://doi.org/10.1097/CAD.0000000000000211). [PubMed: [25603021](https://pubmed.ncbi.nlm.nih.gov/25603021/)].
- Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. *Nature.* 2001;**414**(6866):916-20. doi: [10.1038/414916a](https://doi.org/10.1038/414916a). [PubMed: [11780065](https://pubmed.ncbi.nlm.nih.gov/11780065/)].
- Brown RM, Short JL. Adenosine A(2A) receptors and their role in drug addiction. *J Pharm Pharmacol.* 2008;**60**(11):1409-30. doi: [10.1211/jpp.60.11.0001](https://doi.org/10.1211/jpp.60.11.0001). [PubMed: [18957161](https://pubmed.ncbi.nlm.nih.gov/18957161/)].
- Cunha RA, Ferre S, Vaugeois JM, Chen JF. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. *Curr Pharm Des.* 2008;**14**(15):1512-24. [PubMed: [18537674](https://pubmed.ncbi.nlm.nih.gov/18537674/)].
- Mingote S, Font L, Farrar AM, Vontell R, Worden LT, Stopper CM, et al. Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway. *J Neurosci.* 2008;**28**(36):9037-46. doi: [10.1523/JNEUROSCI.1525-08.2008](https://doi.org/10.1523/JNEUROSCI.1525-08.2008). [PubMed: [18768698](https://pubmed.ncbi.nlm.nih.gov/18768698/)].

10. Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Yee H, et al. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. *Br J Pharmacol*. 2006;**148**(8):1144-55. doi: [10.1038/sj.bjp.0706812](https://doi.org/10.1038/sj.bjp.0706812). [PubMed: [16783407](https://pubmed.ncbi.nlm.nih.gov/16783407/)].
11. Hasko G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. *J Leukoc Biol*. 2008;**83**(3):447-55. doi: [10.1189/jlb.0607359](https://doi.org/10.1189/jlb.0607359). [PubMed: [18160539](https://pubmed.ncbi.nlm.nih.gov/18160539/)].
12. Reinstein LJ, Lichtman SN, Currin RT, Wang J, Thurman RG, Lemasters JJ. Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A2 receptors on rat Kupffer cells. *Hepatology*. 1994;**19**(6):1445-52. [PubMed: [8188175](https://pubmed.ncbi.nlm.nih.gov/8188175/)].
13. Lesurtel M, Lehmann K, de Rougemont O, Clavien PA. Clamping techniques and protecting strategies in liver surgery. *HPB (Oxford)*. 2009;**11**(4):290-5. doi: [10.1111/j.1477-2574.2009.00066.x](https://doi.org/10.1111/j.1477-2574.2009.00066.x). [PubMed: [19718355](https://pubmed.ncbi.nlm.nih.gov/19718355/)].
14. Gurusamy KS, Gonzalez HD, Davidson BR. Current protective strategies in liver surgery. *World J Gastroenterol*. 2010;**16**(48):6098-103. [PubMed: [21182224](https://pubmed.ncbi.nlm.nih.gov/21182224/)].
15. Carini R, De Cesaris MG, Splendore R, Vay D, Domenicotti C, Nitti MP, et al. Signal pathway involved in the development of hypoxic preconditioning in rat hepatocytes. *Hepatology*. 2001;**33**(1):131-9. doi: [10.1053/jhep.2001.21050](https://doi.org/10.1053/jhep.2001.21050). [PubMed: [11124829](https://pubmed.ncbi.nlm.nih.gov/11124829/)].
16. Carini R, Grazia De Cesaris M, Splendore R, Baldanzi G, Nitti MP, Alchera E, et al. Role of phosphatidylinositol 3-kinase in the development of hepatocyte preconditioning. *Gastroenterology*. 2004;**127**(3):914-23. [PubMed: [15362046](https://pubmed.ncbi.nlm.nih.gov/15362046/)].
17. Dal Ponte C, Alchera E, Follenzi A, Imarisio C, Prat M, Albano E, et al. Pharmacological preconditioning protects against hepatic ischemia/reperfusion injury. *Liver Transpl*. 2011;**17**(4):474-82. doi: [10.1002/lt.22256](https://doi.org/10.1002/lt.22256). [PubMed: [21445931](https://pubmed.ncbi.nlm.nih.gov/21445931/)].
18. Peralta C, Hotter G, Closa D, Prats N, Xaus C, Gelpi E, et al. The protective role of adenosine in inducing nitric oxide synthesis in rat liver ischemia preconditioning is mediated by activation of adenosine A2 receptors. *Hepatology*. 1999;**29**(1):126-32. doi: [10.1002/hep.510290104](https://doi.org/10.1002/hep.510290104). [PubMed: [9862858](https://pubmed.ncbi.nlm.nih.gov/9862858/)].
19. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. *BMC Med*. 2014;**12**:145. doi: [10.1186/s12916-014-0145-y](https://doi.org/10.1186/s12916-014-0145-y). [PubMed: [25242656](https://pubmed.ncbi.nlm.nih.gov/25242656/)].
20. Peralta C, Serafin A, Fernandez-Zabalegui L, Wu ZY, Rosello-Catafau J. Liver ischemic preconditioning: a new strategy for the prevention of ischemia-reperfusion injury. *Transplant Proc*. 2003;**35**(5):1800-2. [PubMed: [12962800](https://pubmed.ncbi.nlm.nih.gov/12962800/)].
21. Schmidt R. Hepatic organ protection: from basic science to clinical practice. *World J Gastroenterol*. 2010;**16**(48):6044-5. [PubMed: [21182218](https://pubmed.ncbi.nlm.nih.gov/21182218/)].
22. Hilmi I, Horton CN, Planinsic RM, Sakai T, Nicolau-Raducu R, Damian D, et al. The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation. *Liver Transpl*. 2008;**14**(4):504-8. doi: [10.1002/lt.21381](https://doi.org/10.1002/lt.21381). [PubMed: [18383079](https://pubmed.ncbi.nlm.nih.gov/18383079/)].
23. Zhai Y, Petrowsky H, Hong JC, Busuttill RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation—from bench to bedside. *Nat Rev Gastroenterol Hepatol*. 2013;**10**(2):79-89. doi: [10.1038/nrgastro.2012.225](https://doi.org/10.1038/nrgastro.2012.225). [PubMed: [23229329](https://pubmed.ncbi.nlm.nih.gov/23229329/)].
24. Alchera E, Dal Ponte C, Imarisio C, Albano E, Carini R. Molecular mechanisms of liver preconditioning. *World J Gastroenterol*. 2010;**16**(48):6058-67. [PubMed: [21182220](https://pubmed.ncbi.nlm.nih.gov/21182220/)].
25. Ben-Ari Z, Pappo O, Sulkes J, Cheporko Y, Vidne BA, Hochhauser E. Effect of adenosine A2A receptor agonist (CGS) on ischemia/reperfusion injury in isolated rat liver. *Apoptosis*. 2005;**10**(5):955-62. doi: [10.1007/s10495-005-0440-3](https://doi.org/10.1007/s10495-005-0440-3). [PubMed: [16151631](https://pubmed.ncbi.nlm.nih.gov/16151631/)].
26. Harada N, Okajima K, Murakami K, Usune S, Sato C, Ohshima K, et al. Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. *J Pharmacol Exp Ther*. 2000;**294**(3):1034-42. [PubMed: [10945856](https://pubmed.ncbi.nlm.nih.gov/10945856/)].
27. Mandili G, Alchera E, Merlin S, Imarisio C, Chandrashekar BR, Riganti C, et al. Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2aR stimulation. *J Hepatol*. 2015;**62**(3):573-80. doi: [10.1016/j.jhep.2014.10.007](https://doi.org/10.1016/j.jhep.2014.10.007). [PubMed: [25315650](https://pubmed.ncbi.nlm.nih.gov/25315650/)].
28. Nakayama H, Yamamoto Y, Kume M, Yamagami K, Yamamoto H, Kimoto S, et al. Pharmacologic stimulation of adenosine A2 receptor supplants ischemic preconditioning in providing ischemic tolerance in rat livers. *Surgery*. 1999;**126**(5):945-54. [PubMed: [10568196](https://pubmed.ncbi.nlm.nih.gov/10568196/)].
29. Tang LM, Wang YP, Wang K, Pu LY, Zhang F, Li XC, et al. Protective effect of adenosine A2A receptor activation in small-for-size liver transplantation. *Transpl Int*. 2007;**20**(1):93-101. doi: [10.1111/j.1432-2277.2006.00394.x](https://doi.org/10.1111/j.1432-2277.2006.00394.x). [PubMed: [17181659](https://pubmed.ncbi.nlm.nih.gov/17181659/)].
30. Fredholm BB, I. Jzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev*. 2001;**53**(4):527-52. [PubMed: [11734617](https://pubmed.ncbi.nlm.nih.gov/11734617/)].
31. Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, Chen JF, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. *J Clin Invest*. 2003;**112**(6):883-91. doi: [10.1172/JCI15483](https://doi.org/10.1172/JCI15483). [PubMed: [12975473](https://pubmed.ncbi.nlm.nih.gov/12975473/)].
32. Mathie RT, Alexander B, Ralevic V, Burnstock G. Adenosine-induced dilatation of the rabbit hepatic arterial bed is mediated by A2-purinoreceptors. *Br J Pharmacol*. 1991;**103**(1):1103-7. [PubMed: [1878748](https://pubmed.ncbi.nlm.nih.gov/1878748/)].
33. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. *Pharmacol Rev*. 1998;**50**(3):413-92. [PubMed: [9755289](https://pubmed.ncbi.nlm.nih.gov/9755289/)].
34. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. *World J Gastroenterol*. 2014;**20**(23):7312-24. doi: [10.3748/wjg.v20.i23.7312](https://doi.org/10.3748/wjg.v20.i23.7312). [PubMed: [24966602](https://pubmed.ncbi.nlm.nih.gov/24966602/)].
35. Minor T, Akbar S, Yamamoto Y. Adenosine a2 receptor stimulation protects the predamaged liver from cold preservation through activation of cyclic adenosine monophosphate-protein kinase a pathway. *Liver Transplantation*. 2000;**6**(2):196-200.